PreComb is at the forefront of biotechnology, focusing on enhancing cancer patient outcomes through its innovative 3DTwin® drug testing platform. This technology is designed to address the unique genetic variations that influence how patients respond to cancer treatments. By utilizing a 3D tumor model, PreComb aims to identify therapies that can lead to sustainable tumor regression, thereby offering a more personalized approach to oncology. The company collaborates with leading clinical partners to ensure that physicians have access to a diverse range of drug options, ultimately improving treatment efficacy and patient outcomes.

The 3DTwin® technology represents a significant advancement in precision oncology, bridging the gap between drug discovery and clinical application. PreComb's platform incorporates proprietary screening and automation technologies that expedite the drug discovery process, allowing for quicker access to new therapies for patients. Additionally, the integration of advanced digitalization techniques enables the analysis of extensive clinical data, empowering healthcare providers to make informed treatment decisions. By embracing functional drug profiling, PreComb is paving the way for a new era in personalized medicine, enhancing the efficiency and effectiveness of cancer treatment strategies.

Switzerland

PreCombTherapeutics AG is a privately held Swiss biotechcompany focused on in vitro cancer diagnostic to improve cancer management. It's automated microtumor-based 3DTwin™ technology enables clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome.

PreComb

Company Details